Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Safety and Effectiveness of Compounded Galenic Cholic Acid for Bile Acid Synthesis Disorder: A Case Report

Author(s): Davide Zanon, Francesca Burlo*, Gaia Scaramuzza, Natalia Maximova, Lorenza Matarazzo, Giuseppe Maggiore and Egidio Barbi

Volume 22, Issue 10, 2022

Published on: 22 June, 2022

Page: [1047 - 1052] Pages: 6

DOI: 10.2174/1871530322666220407114607

Price: $65

Abstract

Background: Bile acid synthesis disorders are rare congenital diseases that can lead to cirrhosis and end-stage liver disease if left untreated. Cholic acid administration is the only treatment that can prevent patients from fatal outcomes. Since 2013 in Europe, there has been just one formulation of cholic acid: Orphacol®. It is difficult to administer to infant patients because of its formulation (capsules) and the need for dose titration depending on the patient’s weight.

Case Presentation: Two sisters affected by 3-β-hydroxy-Δ-5-C27-steroid dehydrogenase deficiency showed soon after birth failure to thrive, cholestasis, and fat-soluble vitamin deficiency. Both biochemical findings and liver biopsies confirmed cholestasis and initial liver damage. Patients were treated for eight years with a liquid formulation of a cholic acid galenic compound, and then they started to be treated with capsules of the registered drug. Clinical conditions and biochemical findings were checked periodically during both therapies.

Conclusion: Clinical and laboratory data showed no differences between the cholic acid galenic compound and the registered drug in terms of efficacy and safety. Furthermore, the galenic compound showed benefits of more manageable dose titration, easier intake due to its liquid formulation, and lower costs than commercial cholic acid capsules.

Keywords: Case report, cholic acid, bile acids, synthesis disorder, cholestasis, galenic, infant.

« Previous Next »
Graphical Abstract

[1]
Heubi, J.E.; Setchell, K.D.; Bove, K.E. Inborn errors of bile acid metabolism. Semin. Liver Dis., 2007, 27(3), 282-294.
[http://dx.doi.org/10.1055/s-2007-985073] [PMID: 17682975]
[2]
Bove, K.E.; Heubi, J.E.; Balistreri, W.F.; Setchell, K.D. Bile acid synthetic defects and liver disease: A comprehensive review. Pediatr. Dev. Pathol., 2004, 7(4), 315-334.
[http://dx.doi.org/10.1007/s10024-002-1201-8] [PMID: 15383928]
[3]
Sundaram, S.S.; Bove, K.E.; Lovell, M.A.; Sokol, R.J. Mechanisms of disease: Inborn errors of bile acid synthesis. Nat. Clin. Pract. Gastroenterol. Hepatol., 2008, 5(8), 456-468.
[http://dx.doi.org/10.1038/ncpgasthep1179] [PMID: 18577977]
[4]
Vaz, F.M.; Ferdinandusse, S. Bile acid analysis in human disorders of bile acid biosynthesis. Mol. Aspects Med., 2017, 56, 10-24.
[http://dx.doi.org/10.1016/j.mam.2017.03.003] [PMID: 28322867]
[5]
Chiang, J.Y. Bile acid regulation of gene expression: Roles of nuclear hormone receptors. Endocr. Rev., 2002, 23(4), 443-463.
[http://dx.doi.org/10.1210/er.2000-0035] [PMID: 12202460]
[6]
Setchell, K.D.; Heubi, J.E. Defects in bile acid biosynthesis-diagnosis and treatment. J. Pediatr. Gastroenterol. Nutr., 2006, 43(Suppl. 1), S17-S22.
[http://dx.doi.org/10.1097/01.mpg.0000226386.79483.7b] [PMID: 16819396]
[7]
Daugherty, C.C.; Setchell, K.D.; Heubi, J.E.; Balistreri, W.F. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (delta 4-3-oxosteroid 5 beta-reductase deficiency). Hepatology, 1993, 18(5), 1096-1101.
[http://dx.doi.org/10.1002/hep.1840180513] [PMID: 8225213]
[8]
Gonzales, E.; Gerhardt, M.F.; Fabre, M.; Setchell, K.D.; Davit-Spraul, A.; Vincent, I.; Heubi, J.E.; Bernard, O.; Jacquemin, E. Oral cholic acid for hereditary defects of primary bile acid synthesis: A safe and effective long-term therapy. Gastroenterology, 2009, 137(4), 1310- 1320.e1, 3.
[http://dx.doi.org/10.1053/j.gastro.2009.07.043] [PMID: 19622360]
[9]
Gonzales, E.; Matarazzo, L.; Franchi-Abella, S.; Dabadie, A.; Cohen, J.; Habes, D.; Hillaire, S.; Guettier, C.; Taburet, A.M.; Myara, A.; Jacquemin, E. Cholic acid for primary bile acid synthesis defects: A life-saving therapy allowing a favorable outcome in adulthood. Orphanet J. Rare Dis., 2018, 13(1), 190.
[http://dx.doi.org/10.1186/s13023-018-0920-5] [PMID: 30373615]
[10]
Istituto poligrafico e Zecca dello Stato. Italian Pharmacopoeia, 12th ed; Italian State Printing Works and Mint, 2008, pp. 1416-1425.
[11]
Heubi, J.E.; Bove, K.E.; Setchell, K.D.R. Oral cholic acid is efficacious and well tolerated in patients with bile acid synthesis and zellweger spectrum disorders. J. Pediatr. Gastroenterol. Nutr., 2017, 65(3), 321-326.
[http://dx.doi.org/10.1097/MPG.0000000000001657] [PMID: 28644367]
[12]
Zoellner, Y.; Balp, M.M.; Marco, A.G. The role of galenic innovation in improving treatment compliance and persistence: Three case studies. Clinicoecon. Outcomes Res., 2011, 3, 109-116.
[http://dx.doi.org/10.2147/CEOR.S23158] [PMID: 22046101]
[13]
Rehn, C.; Odouard, E.; Poncet, F.; Cochat, P.; Breant, V.; Dode, X. Facteurs influençant l’acceptabilité des formulations galéniques en pédiatrie – revue de la littérature. Ann. Pharm. Fr., 2018, 76(3), 163-171.
[http://dx.doi.org/10.1016/j.pharma.2018.01.004] [PMID: 29502801]
[14]
National Official Gazette. Ordinary supplement n. 34. February 10, 2017. Available from: https://www.gazzettaufficiale.it/eli/gu/2017/02/10/34/so/9/sg/pdf (Accessed on February 28, 2022).

Rights & Permissions Print Cite
Article Metrics
22
1
© 2024 Bentham Science Publishers | Privacy Policy